Protein kinase CD (PKCD) regulates cell apoptosis and survival in diverse cellular systems. PKCD translocates to different subcellular sites in response to apoptotic stimuli; however, the role of its subcellular localization in its proapoptotic and antiapoptotic functions is just beginning to be understood. Here, we used a PKCD constitutively active mutant targeted to the cytosol, nucleus, mitochondria, and endoplasmic reticulum (ER) and examined whether the subcellular localization of PKCD affects its apoptotic and survival functions. PKCD-Cyto, PKCD-Mito, and PKCD-Nuc induced cell apoptosis, whereas no apoptosis was observed with the PKCD-ER. PKCD-Cyto and PKCD-Mito underwent cleavage, whereas no cleavage was observed in the PKCD-Nuc and PKCD-ER. Similarly, caspase-3 activity was increased in cells overexpressing PKCD-Cyto and PKCD-Mito. In contrast to the apoptotic effects of the PKCD-Cyto, PKCD-Mito, and PKCD-Nuc, the PKCD-ER protected the cells from tumor necrosis factor -related apoptosis-inducing ligand -induced and etoposideinduced apoptosis. Moreover, overexpression of a PKCD kinase-dead mutant targeted to the ER abrogated the protective effect of the endogenous PKCD and increased tumor necrosis factor -related apoptosis-inducing ligand -induced apoptosis. The localization of PKCD differentially affected the activation of downstream signaling pathways. PKCD-Cyto increased the phosphorylation of p38 and decreased the phosphorylation of AKT and the expression of X-linked inhibitor of apoptosis protein, whereas PKCD-Nuc increased c-Jun NH 2 -terminal kinase phosphorylation. Moreover, p38 phosphorylation and the decrease in X-linked inhibitor of apoptosis protein expression played a role in the apoptotic effect of PKCD-Cyto, whereas c-Jun NH 2 -terminal kinase activation mediated the apoptotic effect of PKCD-Nuc. Our results indicate that the subcellular localization of PKCD plays important roles in its proapoptotic and antiapoptotic functions and in the activation of downstream signaling pathways.
Introduction
The ubiquitously expressed isoform protein kinase Cy (PKCy) has been shown to regulate cell apoptosis and survival in various cells depending on the specific cellular system and apoptotic stimuli (1) (2) (3) . Most studies report a proapoptotic function of PKCy in response to various stimuli, such as H 2 O 2 (4), ceramide (5), tumor necrosis factor-a (6) , and the DNAdamaging agents UV radiation (7), cisplatin (8) , and etoposide (9) . Different apoptotic stimuli induce caspase-dependent cleavage of PKCy, which result in the generation of a constitutively active catalytic fragment (10, 11) . The cleavage of PKCy has been implicated in its apoptotic function (12, 13) , and the expression of the catalytic fragment has been shown to induce cell apoptosis in different cellular systems (14, 15) . The apoptotic function of PKCy has been associated with the activation of multiple signaling proteins, such as c-Jun NH 2 -terminal kinase (JNK; ref. 16 ), p38 (17) , AKT (18) , p73 (19) , DNA-PK (20) , scramblase 3 (21) , and lamin B (22) .
In addition to its apoptotic functions, PKCy has been also reported to exert antiapoptotic effects. Thus, PKCy protects macrophages from apoptosis induced by nitric oxide (23) and exerts antiapoptotic effects on glioma cells treated with tumor necrosis factor -related apoptosis-inducing ligand (TRAIL; ref. 24) or infected with a virulent strain of Sindbis virus (25) . Similarly, PKCy promotes survival and chemotherapeutic drug resistance of non -small cell lung cancer cells (26) .
One of the factors that may contribute to the diverse effects of PKCy on cell apoptosis is its different subcellular localization. Indeed, various apoptotic stimuli induce translocation of PKCy to distinct subcellular sites. Thus, PKCy translocates to the Golgi in response to ceramide and IFN-g (5, 27) to the mitochondria in response to oxidative stress, UV radiation, and phorbol 12-myristate 13-acetate (28, 29) and to the nucleus in response to etoposide, g-irradiation, and cytosine arabinoside (9, 30) . Translocation of PKCy to the Golgi, mitochondria, and nucleus in response to these apoptotic stimuli has been associated with proapoptotic effects of this isoform (5, 9, 28) . In addition, PKCy has been shown to translocate to the endoplasmic reticulum (ER) in cells infected with Sindbis virus and in glioma cells treated with TRAIL, where PKCy exerts antiapoptotic effects (24, 25) . Although these studies suggest different functions of PKCy in the various subcellular sites, the role of the translocation of PKCy in its proapoptotic and antiapoptotic effects and in the activation of downstream signaling pathways is largely not defined.
In this study, we explored the role of the subcellular localization of PKCy in its proapoptotic and antiapoptotic functions. Specifically, we asked whether the localization of PKCy in the ER provides antiapoptotic signals as opposed to proapoptotic signals in the mitochondria and nucleus and how the localization of PKCy in the distinct subcellular sites affects the activation of downstream signaling pathways. For these experiments, we targeted PKCy to the cytoplasm, mitochondria, nucleus, and ER using the pShooter vectors, which have been widely used to examine the role of the subcellular localization of various proteins in their specific cellular functions (31) (32) (33) . We found that overexpression of a constitutively active form of PKCy (PKCy-CA) in the cytosol, mitochondria, or nucleus resulted in cell apoptosis. In contrast, expression of PKCy-CA in the ER had no apoptotic effect but it rather protected glioma and HeLa cells against TRAIL-and etoposide-induced apoptosis. In addition, we found that the subcellular localization of PKCy had an important role in the induction of distinct apoptosis-related signaling pathways.
Results
Targeted Localization of PKCdCA in Distinct Subcellular Sites of the A172 Glioma Cells
PKCy has been associated with the regulation of both cell apoptosis and survival (3, 6, 8, 9, 24, 30) . One of the factors that may contribute to the diversity of PKCy effects is its ability to localize to different subcellular sites. To examine the role of PKCy localization in its proapoptotic and antiapoptotic functions, we used a PKCy constitutively active mutant that was targeted to the cytosol (PKCy-Cyto), mitochondria (PKCyMito), nucleus (PKCy-Nuc), and ER (PKCy-ER) using the pShooter vectors (31) (32) (33) . A172 cells were transiently transfected with the different pShooter vectors, and the localization of PKCy was examined using anti-Myc antibody (Fig. 1A) . In parallel, A172 cells were transfected with the corresponding FIGURE 1. Subcellular localization of the PKCy pShooter vectors. A172 cells were transfected with control vector, PKCyCyto, PKCy-Mito, PKCy-Nuc, and PKCy-ER. A. Cells were fixed with 4% paraformaldehyde and then incubated with a rabbit anti-Myc antibody for 1 h followed by incubation with an anti-rabbit Alexa Fluor 488 antibody. Cells were visualized by confocal microscopy. In parallel, cells were transfected with the appropriate pShooter vectors encoding GFP, which served as positive controls. B. The localization of the GFP was visualized using confocal microscopy. C. Colocalization of PKCy-ER, PKCy-Nuc, and PKCy-Mito with the specific organelle markers, anti-calnexin, 7-AAD, and MitoTracker Orange, was determined in cells overexpressing the respective pShooter vectors. The localization of PKCy is shown in green (left ), the ER. Mitochondria and nucleus staining are shown in red (middle ) and the merge image (right ) is yellow for the overlapping red and green signals. The results are from one representative experiment out of three similar experiments.
pShooter vectors encoding green fluorescent protein (GFP), which have been used as positive controls (Fig. 1B) . Figure 1 shows immunostaining of A172 cells transfected with the different pShooter vectors using anti-Myc antibody and A172-expressing GFP pShooter vectors. The expression of PKCy was selectively localized to the cytoplasm, nucleus, mitochondria, and ER in the PKCy-Cyto, PKCy-Nuc, PKCy-Mito, and PKCy-ER, respectively (Fig. 1A) . The localization of PKCy in the different subcellular sites was similar to that of the corresponding GFP pShooter vectors (Fig. 1B) .
The localization of the different PKCy shooter vectors in their respective subcellular sites was also shown using the ER marker anti-calnexin, the nuclear marker 7-aminoactinomycin D (7-AAD), and the mitochondria marker MitoTracker Orange. Figure 1C shows that anti-calnexin, 7-AAD, and MitoTracker Orange exhibited similar patterns to that of PKCy-ER, PKCyNuc, and PKCy-Mito, respectively. Moreover, merged images clearly showed colocalization of the green fluorescence of PKCy-ER, PKCy-Nuc, and PKCy-Mito with the red fluorescence of calnexin, 7-AAD, and MitoTracker Orange, respectively. In contrast, the PKCy-Cyto did not colocalize with any of the organelle markers that were used in this study (data not shown).
Overexpression of PKCd-CA in the Cytoplasm, Mitochondria, and Nucleus, but not in the ER, Induces Cell Apoptosis
We next examined the effect of the organelle-targeted PKCy on cell apoptosis. For these experiments, we used both the A172 and the HeLa cells. Following transfection with the various PKCy pShooter vectors, the expression of PKCy was determined using anti-Myc antibody ( Fig. 2A) and cell apoptosis was determined using propidium iodide staining and fluorescence-activated cell sorting (FACS) analysis and by anti -histone ELISA. As shown in Fig. 2B , transfection of A172 cells with the PKCy-Cyto, PKCy-Mito, and PKCy-Nuc induced a large degree of cell apoptosis in the cells. The most significant effect was induced by the PKCy-Nuc and PKCyMito, whereas a smaller effect was observed with the PKCyCyto. The apoptotic effect was first observed after 24 h of the transfection, and by 48 h thereafter, the majority of the cells were apoptotic (data not shown). In contrast, cell apoptosis was not induced by the PKCy-ER by 24 h (Fig. 2B ) or 48 h after transfection (data not shown). Overexpression of the A172 cells with the PKCy-ER also did not induce major morphologic changes in the cells, whereas cells overexpressing the PKCyCyto, PKCy-Mito, and PKCy-Nuc exhibited apoptotic morphology (Fig. 2C) . Similar results were obtained using antihistone ELISA (Fig. 2D) .
We also examined the effect of the different PKCy pShooter vectors in the HeLa cells and found similar results. Thus, PKCy-Cyto, PKCy-Mito, and PKCy-Nuc induced cell apoptosis, whereas no apoptosis was observed in cells overexpressing PKCy-ER (Fig. 2E) .
Targeting PKCd to Distinct Subcellular Sites Results in Differential Cleavage of PKCd and Activation of Caspase-3
The induction of cell apoptosis by PKCy has been associated with cleavage of this isoform and with the generation of a constitutively active catalytic fragment (4, 9, 13, 30) ; however, the role of PKCy localization in its cleavage is not well characterized. We therefore examined the cleavage of PKCy in cells overexpressing the different PKCy pShooter vectors. The expression of the ectopic PKCy was detected using Western blot analysis and an anti-PKCy antibody that preferentially recognizes the rat PKCy and not the human kinase. As presented in Fig. 3A , overexpression of the PKCy-CA in the cytoplasm and in the mitochondria resulted in cleavage of PKCy and in the accumulation of a 40-kDa catalytic fragment, whereas no significant cleavage was observed in PKCy-Nuc and PKCy-ER. Similar results were obtained using an anti-Myc antibody that recognizes the COOH-terminal Myc tag ( Fig. 2A) .
The cleavage of PKCy is mostly mediated by caspase-3, which is activated by PKCy (6, 9, 12) . Therefore, we examined Figure 3B shows that overexpression of PKCy-Cyto and PKCy-Mito significantly increased the activity of caspase-3 compared with control vector -expressing cells, whereas only a slight increase was observed in the PKCyNuc -overexpressing cells. In contrast, no increase in the activation of caspase-3 was observed in cells overexpressing the PKCy-ER.
To examine the role of caspase-3 activity in the cleavage of PKCy in the different subcellular sites and in the apoptosis induced by the PKCy-Cyto and the PKCy-Mito, we used the caspase-3 inhibitor DEVD-FMK (10 Amol/L). Treatment of the cells with DEVD-FMK following the transfection of the cells with the different pShooter vectors decreased the cleavage of the PKCy-Cyto and the PKCy-Mito (Fig. 3C ). In addition, treatment of the cells with the caspase-3 inhibitor markedly reduced the apoptosis induced by the PKCy-Cyto and PKCyMito and only moderately decreased the apoptotic effect of PKCy-Nuc (Fig. 3D) .
PKCy has been reported to activate the mitochondrial pathway, which eventually leads to the activation of caspase-3 (14, 29) . To examine the role of PKCy localization in the activation of the mitochondrial pathway, we examined its effect on cytochrome c release and on caspase-9 activation. As presented in Fig. 3E , PKCy-Mito significantly increased the release of cytochrome c from the mitochondria to the cytosol, whereas a smaller effect was observed with the PKCy-Cyto and no significant effects were observed with the PKCy-Nuc and PKCy-ER. Similarly, the PKCy-Mito significantly increased the activation of caspase-9, whereas smaller increase was obtained in the PKCy-Cyto -overexpressing cells (Fig. 3F ).
Targeting of PKCd to the ER Protects Glioma and HeLa Cells against Cell Apoptosis
Recent studies in our laboratory showed that PKCy translocated to the ER in response to TRAIL treatment (24) and Sindbis virus neurovirulent infection (25) and that in both cases PKCy acted as a survival kinase. As we have found that PKCy-ER does not induce apoptosis in either the A172 or HeLa cells, we considered the possibility that expression of PKCy in the ER might actually protect glioma cells against cell apoptosis. We first examined whether the PKCy-ER protected the cells against TRAIL-induced apoptosis. A172 cells were transfected with control vector, PKCy-Nuc, and PKCy-ER, and after 24 h, the cells were treated with TRAIL (100 ng/mL) for an additional 5 h. As presented in Fig. 4A , TRAIL induced f45% cell apoptosis in the control vector A172 cells and increased the apoptotic effect of the PKCy-Nuc (data not shown). In contrast, cells overexpressing the PKCy-ER exhibited lower levels of cell apoptosis and only 20% of the cells underwent cell apoptosis (Fig. 4A) . Similar results were obtained with HeLa cells; in these cells, overexpression of PKCy-ER reduced cell apoptosis by 68% compared with control vector cells (Fig. 4B) . TRAIL did not induce the cleavage of PKCy-ER in either A172 or HeLa cells (data not shown).
We also examined the antiapoptotic effect of the PKCy-ER in etoposide-treated cells. Etoposide induced a 22.5% and 45.6% cell apoptosis in A172 and HeLa cells, respectively. Overexpression of the PKCy-ER in these cells significantly reduced the apoptotic effect of etoposide. Thus, the PKCy-ER almost completely abolished the apoptotic effect of etoposide in A172 cells and reduced HeLa cell apoptosis by 53% (Fig. 4C) . In addition to its protective effects against the apoptotic effects of TRAIL and etoposide, the PKCy-ER partially protected the A172 cells against thapsigargin-and tunicamycin-induced cell death (Fig. 4D) . In these experiments, cells were treated with thapsigargin (2 Ag/mL) and tunicamycin (4 Amol/L) for 36 h and analyzed for cell apoptosis using propidium iodide staining and FACS analysis.
To further study the role of PKCy in the ER, we used a PKCy kinase-dead mutant targeted to the ER to interfere with endogenous PKCy that localizes in this subcellular site. For these experiments, we used the apoptotic stimulus TRAIL, which induces translocation of PKCy to the ER (24) . As a control in this experiment, we used the PKCyKD-Nuc. Figure  4E and F shows the overexpression of the PKCyKD-ER and PKCyKD-Nuc using Western blot analysis (Fig. 4E ) and their localization in the ER and nucleus, respectively, using anti-Myc antibody staining and confocal microscopy ( Fig. 4F) . Figure 4G shows that the PKCyKD-ER slightly increased the apoptosis of the A172 cells but significantly enhanced the apoptotic effect of TRAIL. In contrast, overexpression of a PKCyKD mutant that was targeted to the nucleus did not alter the apoptotic response of the cells to TRAIL. These results suggest that the localization of PKCy in the ER exerts an antiapoptotic effect against TRAIL-induced apoptosis and that inhibition of the endogenous PKCy in the ER increases the apoptotic effect of TRAIL.
PKCd-Cyto and PKCd-Nuc Induce the Activation of Different Signaling Pathways
The proapoptotic and antiapoptotic effects of PKCy are mediated by activating various downstream signaling pathways (3). To identify signaling pathways that are induced by the compartmentalized PKCy, we examined the expression and phosphorylation of various apoptosis-related proteins in cells overexpressing the various PKCy pShooter vectors.
As presented in Fig. 5 , the overexpression of the PKCy-Cyto selectively increased the phosphorylation of p38 and decreased the phosphorylation of AKT and the expression of X-linked inhibitor of apoptosis protein (XIAP), whereas the expression of PKCy-Nuc induced the phosphorylation of JNK. In contrast, we did not detect changes in the phosphorylation of signal transducers and activators of transcription 1 or in the expression of Bax and Bcl 2 in cells overexpressing the different PKCy pShooter vectors.
To further study the role of p38 in the apoptosis induced by the PKCy-Cyto, we first examined the phosphorylation of the upstream effector of p38, MKK3. We found that overexpression of PKCy-Cyto significantly increased the phosphorylation of MKK3/MKK6 compared with the control vector cells (Fig. 6A) . To examine the role of p38 in the apoptotic effect of PKCy-Cyto, we first used the p38 inhibitor SB203580. We found that SB203580 (10 Amol/L) almost completely inhibited the phosphorylation of p38 induced by the PKCy-Cyto (Fig. 6B) , whereas it only moderately reduced the apoptosis of these cells (Fig. 6C) . Similar results were obtained with silencing of p38 using specific small interfering RNA (siRNA) duplexes. Thus, transfection of the A172 cells with p38 siRNA duplexes significantly reduced p38 expression (Fig. 6D) , whereas it only moderately abrogated the apoptotic effect of PKCy-Cyto (Fig. 6E) , suggesting that the phosphorylation of p38 only partially contributed to the apoptosis induced by the PKCy-Cyto. In contrast, overexpression of XIAP (Fig. 6F) , which was significantly decreased in the PKCy-Cyto -overexpressing cells, significantly abolished the apoptotic effect of the PKCy-Cyto (Fig. 6G) .
PKCy-Nuc did not affect the phosphorylation of p38 but rather increased the activation of JNK. To delineate the mechanisms by which JNK is activated in the PKCy-Nucoverexpressing cells, we examined the phosphorylation of MKK4 and MKK7 in these cells. As presented in Fig. 7A , overexpression of PKCy-Nuc increased the phosphorylation of MKK7, whereas no increase was observed in the phosphorylation of MKK4. To examine the role of JNK in the apoptotic effect of PKCy-Nuc, we used the JNK inhibitor SP600125. For these experiments, the A172 cells were transfected with the control vector and PKCy-Nuc and treated with the pharmacologic inhibitor 3 h after transfection. Treatment of the PKCy-Nuc -overexpressing cells with the JNK inhibitor SP600125 (20 Amol/L) significantly abolished the increased phosphorylation of JNK that was observed in these cells (Fig. 7B) . In parallel, SP600125 significantly reduced the apoptotic effect of PKCy-Nuc as was observed by the morphology of the cells (Fig. 7C) and by propidium iodide staining and FACS analysis (Fig. 7D) . Thus, cell apoptosis was decreased from 57.8% in the absence of the JNK inhibitor to 18.3% in its presence. Similar results were obtained with JNK inhibitor III (data not shown).
The role of JNK in the apoptosis induced by the PKCy-Nuc was specific because the SP600125 did not inhibit the apoptosis induced by the PKCy-Cyto. Similarly, the p38 inhibitor SB203580 did not alter the apoptosis induced by the PKCyNuc (Fig. 7E) .
Discussion
PKCy has been reported to play a major role in the regulation of cell apoptosis and survival in response to various stimuli (1-3) . Although most studies report a proapoptotic function of PKCy, there are other studies that show an antiapoptotic effect of this isoform (24, 25) . One of the main factors that affect PKC activity and functions and contributes to the diverse effect of PKC is its subcellular localization (34) . Indeed, PKCy undergoes translocation to distinct subcellular sites in response to various apoptotic stimuli (5, 9, 27-29); however, the role of the subcellular localization of PKCy in its apoptotic functions is just beginning to be understood. In this study, we targeted PKCy to the cytoplasm, ER, nucleus, and mitochondria and examined the role of the localization of PKCy in its proapoptotic and antiapoptotic effects.
The first objective of this study was to find a cellular system that will allow the selective targeting of PKCy to the mitochondria, ER, and nucleus in a way that will resemble as much as possible what happens with the endogenous PKCy. The pShooter vectors seemed to be the best choice for targeting PKCy because these vectors have been widely and successfully used to study the role of the subcellular localization of different proteins in their cellular functions (31) (32) (33) . Thus, this system has been used to show the role of the mitochondrial localization of mutant superoxide dismutase 1 in cell death in a model of familial amyotrophic lateral sclerosis (32) , to study the role of the intracellular localization of transglutaminase in cell death (31) , and to examine the functional coupling of chromogranin with the InsP3R for calcium signaling (33) . Importantly, targeting of PKCy to the mitochondria using the appropriate pShooter vector induced phospholipid scramblase-dependent cell apoptosis similar to the endogenous PKCy (21) .
We found that the expression of PKCy-Cyto, PKCy-Mito, and PKCy-Nuc induced cell apoptosis, whereas expression of PKCy-ER had no apoptotic effect. The role of the nuclear and mitochondrial localization of PKCy in its apoptotic function has been shown thus far indirectly by studies that reported an association between the translocation of PKCy to the nucleus and mitochondria and its proapoptotic effects. Indeed, the role of the nuclear localization of PKCy in its apoptotic effect has been shown in studies showing that PKCy translocated to the nucleus in response to apoptotic stimuli, such as etoposide (9, 30) , and that the overexpression of a PKCy nuclear localization signal (NLS) mutant abrogates the apoptotic effect of this drug (35) . Similarly, PKCy has been shown to translocate to the mitochondria in response to UV radiation (14) , phorbol 12-myristate 13-acetate (28) , and oxidative stress (29) and to induce cell apoptosis in response to these stimuli. Our results support these studies and provide direct evidence that the localization of PKCy-CA in the cytosol, mitochondria, and nucleus, but not in the ER, promotes cell apoptosis.
PKCy undergoes cleavage in response to various apoptotic stimuli, such as etoposide (9, 30) , cisplatin (13), UV radiation (14) , and TRAIL (24) . Although the cleavage of PKCy and its catalytic fragment are mainly associated with its proapoptotic effects (9, 13, 14, 30) , in some systems PKCy cleavage does not play a role in its apoptotic effects (36, 37) or it is associated with PKCy protective effects (24) . We found that PKCy-Cyto and PKCy-Mito were cleaved to generate a 40-kDa catalytic fragment. In contrast, the PKCy-Nuc and PKCy-ER did not undergo significant cleavage, although the PKCy-Nuc induced a large degree of cell apoptosis. Although most of the studies implicate the catalytic domain of the nuclear PKCy as an important mediator of its apoptotic activity (9, 19, 20, 35) , our results show that the apoptotic effect of PKCy-Nuc was not dependent on its cleavage and catalytic fragment and that the localization of PKCy in the nucleus was sufficient to induce cell apoptosis.
We found that PKCy-Cyto and PKCy-Mito induced activation of caspase-3, whereas only minor activation of caspase-3 was detected in the PKCy-Nuc overexpressors. The cleavage of PKCy is mainly mediated by caspase-3 (6, 9, 30), which in turn is phosphorylated and activated by PKCy (9, 30, 38) . Thus, the large increase in caspase-3 activation induced by PKCy-Cyto and PKCy-Mito is in accordance with their cleavage. Similarly, inhibition of caspase-3 significantly inhibited the apoptosis induced by PKCy-Cyto and PKCy-Mito, whereas it only slightly abrogated the apoptosis induced by the PKCy-Nuc. These results suggest that PKCy-Nuc induced cell apoptosis mostly in a caspase-3 -independent manner. One of the reasons for the lack of the activation of caspase-3 and PKCy cleavage in the PKCy-Nuc -overexpressing cells may be the different subcellular localization of PKCy relative to that of caspase-3. In a recent study, we reported that etoposide induced colocalization of caspase-3 and PKCy in the nucleus and that caspase-3 induced cleavage of PKCy in this site (9) . However, the localization of caspase-3 in the nucleus was dependent on the activation of caspase-9 by a tyrosine phosphorylated PKCy. Indeed, PKCy-Nuc did not induce cytochrome c release from the mitochondria or the activation of caspase-9.
PKCy-ER did not induce cell apoptosis in either A172 or HeLa cells but rather protected the cells from different apoptotic stimuli. Interestingly, we recently reported that translocation of PKCy to the ER was associated with antiapoptotic effects of this isoform. Thus, PKCy translocated to the ER in response to Sindbis virus infection (25) and in response to TRAIL treatment (24) , and in both cases, PKCy protected the cells from the apoptosis induced by these stimuli. These results are further supported by our current findings that targeting PKCy to the ER reduced cell apoptosis induced by TRAIL and etoposide in both A172 and HeLa cells. In addition to showing the protective effect of the overexpressed PKCy-ER, we also showed that the localization of the endogenous PKCy in the ER has similar protective effect. Thus, expression of a PKCyKD mutant that was targeted to the ER increased the apoptosis induced by TRAIL by abrogating the protective effect of the ER-localized endogenous PKCy. Collectively, these results indicate that PKCy that resides in the ER, either ectopically or endogenously, similarly exerts antiapoptotic effects.
In addition to its protective effects against cell apoptosis, the PKCy-ER partially inhibited cell death induced by thapsigargin and tunicamycin, suggesting that localization of PKCy in the ER had a protective effect also in the ER stress-induced apoptosis. The role of PKCy in the ER and the mechanisms involved in its antiapoptotic effects are currently not understood. Localization in the ER has been described for other PKC isoforms, such as PKCa (39) and PKCD (40) , but the functions of these PKC isoforms in the ER have not been reported. Importantly, there are several apoptosis-related proteins, such as caspase-12, Bcl 2 , Bax, Bik, and Bak (41, 42) , which reside in the ER and play a role in the regulation of cell apoptosis. One possible PKCy substrate in the ER is Bcl 2 , which has been shown to undergo phosphorylation by PKC (43) and to regulate the cross-talk between the ER and the mitochondria during cell apoptosis (44) . Interestingly, a recent study reported that targeting of Bcl 2 to the ER plays an important role in its protective effect (41) . Studies exploring the role of Bcl 2 in the antiapoptotic effects of PKCy-ER and the identification of novel PKCy substrates/partners in the ER are currently under way.
PKCy has been shown to activate a large number of downstream signaling pathways in response to various apoptotic stimuli (3). Thus, the activation of signaling proteins, such as c-Abl (45), JNK (16), p38 (17), p73 (19) , and DNA-PK (20) , has been associated with the proapoptotic effect of PKCy, whereas phosphorylation of AKT (24) and HSP25 (46) is associated with its antiapoptotic effects. We found that the localization of PKCy affected its ability to activate specific downstream signaling pathways. Thus, the PKCy-Cyto induced phosphorylation of p38 and dephosphorylation of AKT and decreased the expression of XIAP, whereas the PKCy-Nuc induced phosphorylation of JNK.
PKCy has been recently reported to increase the phosphorylation of p38 in various cell types (17, 47) . However, the role of the subcellular localization of PKCy in this effect was not reported. We found that the PKCy-Cyto induced the phosphorylation of MKK3/MKK6, which lies upstream of p38 (48) . Although PKCy-Cyto activated the p38 pathway, it played only a partial role in the apoptosis induced by the PKCy-Cyto because the p38 inhibitor SB203580 and silencing of p38 only moderately inhibited cell apoptosis, suggesting that additional signaling pathways mediate the apoptotic effect of the PKCyCyto.
In addition to the phosphorylation of the proapoptotic protein p38, the PKCy-Cyto induced dephosphorylation of AKT, which regulates cell survival in a variety of cellular systems (49) . The survival effects of AKT are exerted by phosphorylating proteins, such as BAD, caspase-9, the forkhead transcription factors (49), or XIAP (50) . Indeed, XIAP has been recently identified as a downstream target of AKT and as an important regulator of AKT survival effects. AKT phosphorylates XIAP on Ser 87 and this phosphorylation stabilizes XIAP and prevents its ubiquitination and degradation (50) . Our results indicate that the PKCy-Cyto reduced the expression of XIAP and that overexpression of XIAP significantly abrogated the apoptotic effect of PKCy-Cyto. Thus, the decrease in XIAP expression contributed to the apoptotic effect of PKCy-Cyto in addition to the moderate effect of p38.
In contrast to the effect of the PKCy-Cyto on the AKT and p38 signaling pathways, overexpression of PKCy-Nuc selectively increased the phosphorylation of JNK, whereas it did not affect the phosphorylation of AKT, p38, and signal transducers and activators of transcription 1 or the expression of Bax, Bcl 2 , or XIAP. To further characterize the effect of PKCy-Nuc on JNK activation, we examined the phosphorylation of two JNK kinases: MKK4 and MKK7. We found that the PKCy-Nuc induced the phosphorylation of MKK7, whereas it did not affect the activation of MKK4. PKCy has been previously shown to activate MKK7 (51); however, this is the first report showing the role of nuclear PKCy in this effect. The JNK pathway played a major role in the apoptotic effect of PKCyNuc because inhibition of JNK significantly decreased the apoptotic effect of the PKCy-Nuc. JNK has been implicated in the regulation of cell apoptosis in response to various stimuli (51, 52) and has been shown to act downstream of PKCy (16, 51, 53, 54) . A role for the nuclear PKCy in the activation of JNK is further supported by recent studies that showed that the nuclear translocation of PKCy by etoposide preceded the activation of JNK in salivary gland acinar cells (30, 53) . Thus, JNK may represent another nuclear PKCy substrate in addition to the already well-characterized substrates, p73 (19) and DNA-PK (20) .
Interestingly, PKCy-Mito did not induce any significant changes in the expression or phosphorylation of the different signaling proteins that were examined in this study, whereas it induced the release of cytochrome c from the mitochondria and the activation of caspase-9. Thus, targeting of PKCy to the mitochondria seems to activate the mitochondrial pathway probably via phosphorylation of mitochondrial-associated proteins, such as scramblase 3, which has been recently identified as a substrate of PKCy in the mitochondria (21) .
Various studies have shown the importance of the subcellular localization of signaling proteins in their biological functions. Indeed, the targeting of Bcl 2 to the mitochondria induces cell apoptosis, whereas its targeting to the ER promotes its protective function (55) . In addition, the localization of extracellular signal-regulated kinase 2 determines its protective effects against different apoptotic stimuli (56). With regard to PKC, numerous studies showed that the subcellular localization of PKC has major roles in the activity, functions, and diverse effects of the different PKC isoform effects (34, 57, 58) . Less is known, however, about the role of the subcellular localization of a specific isoform in its diverse functions in a given cellular system. Our results show that the subcellular localization of PKCy has an important role in its proapoptotic and antiapoptotic functions; proapoptotic effects when localized in the cytosol, mitochondria, and nucleus and antiapoptotic effect in the ER. Moreover, the localization of PKCy differentially activates different downstream signaling pathways. Thus, the results of this study have important implications for our understanding of the role of PKCy localization in its different effects and may provide the basis for the identification of novel PKC substrates/partners in the different subcellular sites and for the development of inhibitors that can selectively block distinct functions of PKCy in a specific cellular system.
Materials and Methods

Materials
An affinity-purified polyclonal anti-PKCy antibody (C-17) was purchased from Santa Cruz Biotechnology, and anti-Myc antibody was from Upstate USA, Inc. Anti-calnexin was from Stressgen, and the nuclear marker 7-AAD and the mitochondria marker MitoTracker Orange were from Molecular Probes, Invitrogen. Human TRAIL was from PeproTech, and antiphosphorylated AKT, AKT, p38, phosphorylated p38, phosphorylated MKK3/MKK6, MKK3, phosphorylated JNK, JNK, phosphorylated MKK7, MKK7, phosphorylated MKK4, MKK4, signal transducers and activators of transcription 1, phosphorylated signal transducers and activators of transcription 1, XIAP, active caspase-3, Bax, and Bcl 2 antibodies were obtained from Cell Signaling Technology. The caspase-3 inhibitor DEVD-FMK, the p38 mitogen-activated protein kinase inhibitor SB202190, and the JNK inhibitors SP600125 and JNK inhibitor III (HIV-TAT 47-57 -gaba-c-Jund ) were from Calbiochem. Etoposide, leupeptin, aprotinin, phenylmethylsulfonyl fluoride, and sodium vanadate were obtained from Sigma Chemical Co.
Cell Culture
The glioma cell lines A172 and HeLa were obtained from the American Type Culture Collection. Cells were grown on tissue culture dishes in medium consisting of DMEM containing 10% heat-inactivated FCS, 2 mmol/L glutamine, 50 units/mL penicillin, and 0.05 mg/mL streptomycin. Medium was changed every 3 to 4 days and cultures were passaged using 0.25% trypsin.
Plasmid Construction
The constitutive active PKCy mutant contains double point mutations of alanine to arginine at positions 144 and 145 in the inhibitory pseudosubstrate sequences within the regulatory domain as described (59) . The pShooter vectors pCMV/myc/ cyto, pCMV/myc/ER, pCMV/myc/mito, and pCMV/myc/nuc were purchased from Invitrogen. The inserts, rat PKCy-CA (constitutively active, DR144/145A) or PKCyKD (kinase-dead, K376A; ref. 9), were digested from the PKCy-CA-EGFP-N1 and PKCyKD plasmids using the XhoI and MluI sites and subcloned into the XhoI/NotI site of the pShooter vectors. The non -organelle-targeted vector was designated PKCy-Cyto, the mitochondria-targeted vector with the mitochondria signal was designated PKCy-Mito, the ER-targeted vectors that contain the ER retention signal were designated PKCy-ER and PKCyKD-ER, and the nucleus-targeted vectors that contain the nuclear localization signal were designated PKCyNuc and PKCyKD-Nuc. Confirmation of proper ligation was done by DNA sequencing. The pCDNA3-XIAP-Myc plasmid (Addgene plasmid 11833) was kindly provided by Dr. Guy Salvesen (University of California, San Diego, CA).
Cell Transfection
A172 cells were transfected either with the control vector or with the different PKCy pShooter vectors by electroporation using the Nucleofector device, protocol number U29 (Amaxa Biosystems). Transfection efficiency using nucleofection was between 70% and 90%.
The attachment of the cells was not significantly altered by the electroporation, and the attachment of the cells overexpressing the different pShooter vectors was similar to that of the control vector.
HeLa cells were transfected using LipofectAMINE (Invitrogen) according to the manufacturer's instructions.
siRNA Transfection
Control (scrambled sequence) and p38 siRNA duplexes were synthesized and purified by Dharmacon. Transfection of siRNAs was done using Oligofectamine (Invitrogen) according to the manufacturer's instructions. Experiments were done 72 h after transfection.
Preparation of Cell Homogenates and Immunoblot Analysis
Cell pellets (10 6 cells/mL) were resuspended in 100 AL of lysis buffer [25 mmol/L Tris-HCl (pH 7.4), 50 mmol/L NaCl, 0.5% sodium deoxycholate, 2% NP40, 0.2% SDS, 1 mmol/L phenylmethylsulfonyl fluoride, 50 Ag/mL aprotinin, 50 Amol/L leupeptin, 0.5 mmol/L Na 3 VO 4 ] on ice for 15 min. Sample buffer (2Â) was added and the samples were boiled for 5 min. Lysates (30 Ag protein) were resolved by SDS-PAGE and transferred to nitrocellulose membranes. The membranes were blocked with 5% dry milk in PBS and subsequently probed with the primary antibody. Specific reactive bands were detected using a goat anti-rabbit or goat anti-mouse IgG conjugated to horseradish peroxidase (Bio-Rad), and the immunoreactive bands were visualized by the enhanced chemiluminescence Western blotting detection kit (Amersham).
Immunofluorescence Staining
Transfected cells were washed with PBS and fixed in 4% paraformaldehyde for 15 min. Subsequently, cells were washed in PBS and, after blocking with staining buffer (2% bovine serum albumin and 0.1% Triton X-100 in PBS) for 30 min at room temperature, incubated with an anti-Myc antibody. Following washes in PBS, cells were incubated with an anti-rabbit Alexa Fluor 488 antibody for additional 60 min and mounted in FluoroGuard antifade reagent. Cells were viewed and photographed using confocal microscopy with Â63 magnification at an excitation wavelength of 488 nm. For the visualization of the ER, cells were incubated with mouse anti-KDEL antibody followed by incubation with anti-mouse Alexa Fluor 546 antibody. Visualization of the nucleus and the mitochondria was done using labeling of the cells with the nuclear marker 7-AAD (10 mg/mL) and with the mitochondria marker MitoTracker Orange (50 nmol/L), respectively.
Cells transfected with the GFP pShooter vectors were fixed in 4% paraformaldehyde for 20 min and mounted in FluoroGuard antifade reagent.
Measurements of Cell Apoptosis
Cell apoptosis was measured using propidium iodide staining and analysis by flow cytometry as described previously (9, 24) . Briefly, transfected cells (1 Â 10 5 /mL) were plated in six-well plates and treated with the indicated treatments for 24 h. Detached cells and trypsinized adherent cells were pooled, fixed in 70% ethanol for 1 h on ice, washed with PBS, and treated for 15 min with RNase (50 Amol/L) at room temperature. Cells were then stained with propidium iodide (5 Ag/mL) and analyzed on a Becton Dickinson cell sorter.
Cell apoptosis was also measured using anti -histone ELISA (Cell Death Detection ELISA kit, Roche Applied Science). For these experiments, extracts of cells containing histone-associated DNA fragments were incubated in 96-well plates coated with anti-histone antibodies for 2 h. Plates were then washed and incubated with anti-DNA antibodies conjugated to peroxidase for an additional 2 h. Substrate solution was added and absorbance was measured at a wavelength of 405 nm.
